MYCN: From oncoprotein to tumor-associated antigen

Frontiers in Oncology

Volumn 2, Issue , 2012, Pages

  Pistoia, Vito ^a   Morandi, Fabio ^a   Pezzolo, Annalisa ^a   Raffaghello, Lizzia ^a   Prigione, Ignazia ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

Cytotoxic T cells; Immunotherapy; MYCN oncoprotein; Neuroblastoma; Tumor antigen

Indexed keywords

EID: 84877933549     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2012.00174     Document Type: Review

References (35)

1. Abbas, A. K., Lichtman, A. H., and Pillai, S. (2011). Cellular and Molecular Immunology. Philadelphia: Elsevier/Saunders.
2. Brodeur, G. M., Seeger, R. C., Schwab, M., Varmus, H. E., and Bishop, J. M. (1984). Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224, 1121–1124.
3. De Verteuil, D., Granados, D. P., Thibault, P., and Perreault, C. (2012). Origin and plasticity of MHC-I associated selfpeptides. Autoimmun. Rev. 11, 627–635.
4. Garson, J. A., McIntyre, P. G., and Kemshead, J. T. (1985). N-myc amplification in malignant astrocytoma. Lancet 2, 718–719.
5. Hendrix, M. J., Seftor, E. A., Hess, A. R., and Seftor, R. E. (2003). Vasculogenic mimicry and tumour-cell plasticity: Lessons from melanoma. Nat. Rev. Cancer 3, 411–421.
6. Himoudi, N., Yan, M., Papanastasiou, A., and Anderson, J. (2008). MYCN as a target for cancer immunotherapy. Cancer Immunol. Immunother. 57, 693–700.
7. Jain, K. K. (2010). Personalized cancer vaccines. Expert Opin. Biol. Ther. 10, 1637–1647.
8. Jakobovits, A., Schwab, M., Bishop, J. M., and Martin, G. R. (1985). Expression of N-myc in teratocarcinoma stem cells and mouse embryos. Nature 318, 188–191.
9. Lee, W. H., Murphree, A. L., and Benedict, W. F. (1984). Expression and amplification of the N-myc gene in primary retinoblastoma. Nature 309, 458–460.
10. Louis, C. U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G. D., et al. (2011). Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050–6056.
11. Malynn, B. A., de Alboran, I. M., O’Hagan, R. C., Bronson, R., Davidson, L., DePinho R. A., et al. (2000). N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev. 14, 1390–1399.
12. Morandi, F., Chiesa, S., Bocca, P., Millo, E., Salis, A., Solari, M., et al. (2006). Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: Immunotherapeutic implications. Neoplasia 8, 833–842.
13. Morandi, F., Levreri, I., Bocca, P., Galleni, B., Raffaghello, L., Ferrone, S., et al. (2007). Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res. 67, 6433–6441.
14. Morgenstern, D. A., and Anderson, J. (2006). MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma. Expert Rev. Anticancer Ther. 6, 217–224.
15. Nisen, P. D., Zimmerman, K. A., Cotter, S. V., Gilbert, F., and Alt, F. W. (1986). Enhanced expression of the N-myc gene in Wilms’ tumors. Cancer Res. 46, 6217–6222.
16. Pelengaris, S., Littlewood, T., Khan, M., Elia, G., and Evan, G. (1999). Reversible activation of c-Myc in skin: Induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell 3, 565–577.
17. Perez, S. A., von Hofe, E., Kallinteris, N. L., Gritzapis, A., Peoples, G. E., Papamichail, M., et al. (2010). A new era in anticancer peptide vaccine. Cancer 116, 2071–2080.
18. Pezzolo, A., Parodi, F., Corrias, M. V., Cinti, R., Gambini, C., and Pistoia, V. (2007). Tumor origin of endothelial cells in human neuroblastoma. J. Clin. Oncol. 25, 376–383.
19. Pezzolo, A., Parodi, F., Marimpietri, D., Raffaghello, L., Cocco, C., Pistorio, A., et al. (2011). Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. Cell Res. 21, 1470–1486.
20. Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., et al. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264–1270.
21. Raffaghello, L., Prigione, I., Airoldi, I., Camoriano, M., Levreri, I., Gambini, C., et al. (2004). Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 6, 558–568.
22. Raffaghello, L., Prigione, I., Bocca, P., Morandi, F., Camoriano, M., Gambini, C., et al. (2005). Multiple defects of the antigen-processing machinery components in human neuroblastoma: Immunotherapeutic implications. Oncogene 24, 4634–4644.
23. Ramos, C. A., and Dotti, G. P. (2011). Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin. Biol. Ther. 11, 855–873.
24. Sarkar, A. K., and Nuchtern, J. G. (2000). Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes. Cancer Res. 60, 1908–1913.
25. Schreiber, R. D., Old, I. J., and Smyth, M. J. (2011). Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science 331, 1565–1570.
26. Seeger, R. C. (2011). Immunology and immunotherapy of neuroblastoma. Semin. Cancer Biol. 21, 229–237.
27. Seliger, B., Maeurer, M. J., and Ferrone, S. (2000). Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21, 455–464.
28. Semsei, I., Ma, S. Y., and Cutler, R. G. (1989). Tissue and age specific expression of the myc proto-oncogene family throughout the life span of the C57BL/6J mouse strain. Oncogene 4, 465–471.
29. Stermann, A., Huebener, N., Seidel, D., Reker, D., and Lode, H. N. (2012). “MYCN-DNA vaccination suppresses growth of MYCN overexpressing neuroblastoma in a syngeneic mouse model,” in Advances in Neuroblastoma Research Conference 2012, Toronto, 103 (abstract).
30. Tanaka, K., and Kasahara, M. (1998). The MHC class I ligand-generating system: Roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28. Immunol. Rev. 163, 161–176.
31. Weiss, W. A., Aldape, K., Mohapatra, G., Feuerstein, B. G., and Bishop, J. M. (1997). Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16, 2985–2995.
32. Williamson, D., Lu, Y. J., Gordon, T., Sciot, R., Kelsey, A., Fisher, C., et al. (2005). Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J. Clin. Oncol. 23, 880–888.
33. Wong, A. J., Ruppert, J. M., Eggleston, J., Hamilton, S. R., Baylin, S. B., and Vogelstein, B. (1986). Gene amplification of c-myc and N-myc in small cell carcinoma of the lung. Science 233, 461–464.
34. Zimmerman, K. A., Yancopoulos, G. D., Collum, R. G., Smith, R. K., Kohl, N. E., Denis, K. A., et al. (1986). Differential expression of myc family genes during murine development. Nature 319, 780–783.
35. Zimmerman, K., Legouy, E., Stewart, V., Depinho, R., and Alt, F. W. (1990). Differential regulation of the N-myc gene in transfected cells and transgenic mice. Mol. Cell. Biol. 10, 2096–2103.